Radioactive iodine is a crucial tool for treatment of differentiated thyroid cancer (DTC). In 5% of cases, DTCs lose I-131 avidity and assume an aggressive behaviour. Treatment options for iodine-refractory DTC are limited. We report the experience of off-label use of the tyrosine kinase inhibitor sorafenib for treatment of advanced iodine-refractory DTC.
Sorafenib in advanced iodine-refractory differentiated thyroid cancer: efficacy, safety and exploratory analysis of role of serum thyroglobulin and FDG-PET / Marotta, V., Ramundo, V., Camera, L., Del Prete, M., Fonti, R., Esposito, R., Palmieri, G., Salvatore, M., Vitale, M., Colao, A., Faggiano, A.. - In: CLINICAL ENDOCRINOLOGY. - ISSN 1365-2265. - 78:5(2013), pp. 760-767. [10.1111/cen.12057]
Sorafenib in advanced iodine-refractory differentiated thyroid cancer: efficacy, safety and exploratory analysis of role of serum thyroglobulin and FDG-PET
Ramundo, Valeria;Faggiano, Antongiulio
2013
Abstract
Radioactive iodine is a crucial tool for treatment of differentiated thyroid cancer (DTC). In 5% of cases, DTCs lose I-131 avidity and assume an aggressive behaviour. Treatment options for iodine-refractory DTC are limited. We report the experience of off-label use of the tyrosine kinase inhibitor sorafenib for treatment of advanced iodine-refractory DTC.| File | Dimensione | Formato | |
|---|---|---|---|
|
Marotta_Sorafenib-iodine-refractory_2013.pdf
solo gestori archivio
Tipologia:
Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza:
Tutti i diritti riservati (All rights reserved)
Dimensione
363.52 kB
Formato
Adobe PDF
|
363.52 kB | Adobe PDF | Contatta l'autore |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
